南京地区医保新增抗感染药物利用分析及医保支付费用预测  

Application analysis and the prediction of medicare payments of the newly selected anti-infective drugs of medical insurance in Nanjing

作　　者：房文通[1] 戴惠珍 张吉[1] Fang Wen-tong;Dai Hui-zhen;Zhang Ji(The First Affiliated Hospital of Nanjing Medical University,Nanjing 210029;Jiangsu Modicine Information Insitute,Nanjing 210029)

机构地区：[1]南京医科大学第一附属医院,南京210029 [2]江苏省医药情报研究所,南京210029

出　　处：《中国抗生素杂志》2018年第10期1305-1311,共7页Chinese Journal of Antibiotics

基　　金：江苏省药学会Shire生物药学科研基金(No.S201602)

摘　　要：目的分析南京地区医保新增抗感染药物2014—2016年的利用情况并预测其纳入医保后的医保支付金额。方法南京地区2014—2016年医保新增抗感染药物及总抗感染药物的用药数据来自江苏省医药情报研究所。药物利用情况以用药金额、用药频度(defined daily doses, DDDs)、日均费用(defined daily cost, DDC)和B/A值表示。结果 2014—2016年医保新增抗感染药物的应用逐年增加,2016年DDDs达617.42千日,用药金额达1723.86万元。3年来用药金额最高的类别均为抗细菌感染药物,DDDs最高的为黄连素。3年来销售金额第一的品种均为替加环素,DDDs第一的品种是小儿黄连素。大部分品种的DDC基本稳定。DDC值较高的达托霉素、替加环素和泊沙康唑,其B/A值均较低。假设均按南京市城镇职工医保报销,若DDDs不变,预测医保支付金额为853.39万元,若DDDs加倍,预测医保支付金额为1706.79万元。结论南京地区医保新增抗感染药物2014—2016年的利用基本合理,纳入"新医保"后,不会对医保支付造成很大负担。Objective To analyze the appfication of newly selected anti-infective drugs of medical insurance in Nanjing city from 2014 to 2016, and to predict its medicare payments. Methods The consumption of the newly selected anti-infective drugs and the total anti-infective drugs in 2014-2016 was obtained from Jiangsu medicine information institute. Drug utilization was expressed as the consumption amount, DDDs, DDC, and B/A value, Results From 2014 to 2016, drug utilization of newly selected anti-infective drugs increased year by year. The DDDs were 617.42 thousand days and the consumpfion amount was 17,238,610 Yuan in 2016. The top in the consumption amount was anti-bacterial infection drugs, while the top in DDDs was other anti-infective drags in 2014-2016. Tigecycline was high at consumption amount, while child berberine was high at DDDs. DDC of most drugs kept stable relatively. The DDC values of daptomycin, tigecycline, and posaconazole were high, while their B/A values were low. If DDDs did not change, the estimated medicare payment was 8.53 million. If DDDs doubled, the estimated medicare payment was 17.07 million. Conclusion The application of the newly selected anti-infective drugs of medical instwance in Nanjing was rational in 2014-2016. Their inclusion in ＂health insurance＂ will not give big burden on medical payments.

关 键 词：抗感染药物 DDDS 用药金额 医疗保险 

分 类 号：R978[医药卫生—药品]